Long-acting β2-agonists: How are they used in an optimal way?

Respiratory Medicine

Volumn 91, Issue 10, 1997, Pages 587-591

  Bjermer, L ^a   Larsson, L ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b ÖSTERSUND HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BAMBUTEROL; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; METHACHOLINE; PREDNISOLONE; SALBUTAMOL; SALMETEROL;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; BRONCHUS OBSTRUCTION; DRUG CHOICE; DRUG SENSITIVITY; DRUG TOLERANCE; DRUG USE; EXERCISE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LONG TERM CARE; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REVIEW; TACHYPHYLAXIS;

EID: 0030692040     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(97)90004-4     Document Type: Review

References (27)

1. 2-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
2. 2-agonists in the treatment of asthma? Chest 1995; 107: 1116-1124.
3. Fitzpatrick MF, Mackay T, Driver H, Douglas NJ. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a longacting inhaled beta-agonist. BMJ 1990; 301: 1365-1368.
4. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Allergol Immunopathol (Madr) 1992; 20: 72-84.
5. Greening A, Wind P, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids. Lancet 1994; 334: 219-224.
6. Woolcock A, Lundbäck Bo, Ringdal N, Jacques LJ. Comparison of addition of salmeterol to inhaled steroids with a doubling of the dose of inhaled steroids. Am J Crit Care Med 1996; 153: 1481-1488.
7. Verberne AAPH, Frost C, Bogaard JM, Kerrebijn KF. One year treatment with salmeterol, compared to inhaled corticosteroid in children with mild to moderate asthma. Am J Respir Crit Care Med 1996; 153 (4): A408.
8. Johnson M. Beta 2-agonists as anti-inflammatory therapies in the lung. Agents Actions Suppl 1993; 41: 27-45.
9. Wallin A, Sandström T, Söderberg M et al. Possible anti-inflammatory action of 2 month treatment with formoteroldry powder: a comparison with budesonide and placebo. Eur Respir J 1996; 9: 271S.
10. Pedersen B, Dahl R, Larsen BB, Venge P. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and post-challenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy 1993; 48: 377-382.
11. Giannini D, Carletti A, Dente FL et al. Tolerance to Salmeterol in allergen-induced bronchoconstriction. Am J Respir Crit Care Med 1995; 152: A39.
12. Cockroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen, see comments. Lancet 1993; 342: 833-837.
13. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363-368.
14. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma, see comments. N Engl J Med 1992; 327: 1198-1203.
15. Bhagat R, Kalra S, Swystun VA, Cockroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-1239.
16. Vathenen AS, Knox AJ, Higgins BG, Britton JRS, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; i: 554-558.
17. Larsson S, Svedmyr N, Thiringer GJ. Lack of bronchial beta-adrenoreceptor resistance in asthmatics during long term treatment with terbutaline. J Clin Allergy Clin Immunol 1977; 59: 93-100.
18. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-206.
19. Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 497-504.
20. Fuglsang G, Agertoft L, Vikre Jörgensen J, Pedersen S. Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. Pediatr Allergy Immunol 1995; 6: 103-108.
21. Hui KKD, Conolly ME, Tasbui DP. Reversal of human lymphocyte beta adrenoceptor desensitisation by glucocorticoids. Clin Pharmac Ther 1982; 32: 566-571.
22. Brodde OE, Brinkman M, Schermuth R, O'Hara N, Daul A. Terbutalin-induced desensitisation of human lymphocyte beta2-receptors. Accelerated restoration of beta-adrenoceptor responses by prednisolone and ketotifen. J Clin Invest 1985; 76: 1096-1101.
23. Karlra S, Swystun VA, Bhagat R, Cockroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-956.
24. Tan KS, Grove A, McLean A, Gnosspelius Y, Lipworth B. Systemic corticosteroid rapidly reverses formoterol induced tachyphylaxis in asthmatic patients. Chest 1996; 108; 343.
25. Tan KS, McFarlane LC. Lipworth B. Effects of prednisolone and fluticasone on lymphocyte beta-2 receptor supsensitivity in asthmatic patients. Br J Clin Pharmacol 1996; 42: 659.
26. Tattersfield AE. Clinical pharmacology of long-acting β-receptor agonists. Life Sci 1993; 52: 2161-2169.
27. Lindén A, Bergendal A, Ullman A, Skoogh BE, Löfdahl C-G. Salmeterol, formoterol and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.